Last reviewed · How we verify
Plenadren
At a glance
| Generic name | Plenadren |
|---|---|
| Also known as | Modified-release hydrocortisone, hydrocortisone modified-release tablet, Dual-release Hydrocortisone |
| Sponsor | Ulla Feldt-Rasmussen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (PHASE4)
- A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
- Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency (PHASE2)
- Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency (PHASE3)
- Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) (PHASE4)
- Optimising Steroid Replacement in Patients With Adrenal Insufficiency (PHASE4)
- Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |